Format

Send to

Choose Destination
See comment in PubMed Commons below
Lupus. 2005;14(3):189-91.

Anti-cytokine therapy in systemic lupus erythematosus.

Author information

1
Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Abstract

In the course of the disease, a wide variety of cytokines is dysregulated, many of which likely influence systemic lupus erythematosus (SLE) autoimmunity and/or lupus tissue inflammation. Proinflammatory cytokines in particular, such as TNF, IL-6, IL-18 or IFN-gamma, may play a major role in propagating the inflammatory processes responsible for tissue damage. These cytokines are overexpressed both systemically and locally, and preliminary results from open-label trials and/or animal studies suggest potential benefits of blocking either of these inflammatory mediators. Since new therapeutic agents may soon offer many ways to influence the process, controlled clinical trials following open-label safety studies are of central importance to arrive at optimized therapies for SLE patients.

PMID:
15807194
DOI:
10.1191/0961203305lu2134oa
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center